Tango Therapeutics Inc
Q1 2025 Earnings
Market Reaction
Did TNGX Beat Earnings? Q1 2025 Results
Tango Therapeutics posted a disappointing first quarter, missing on both the top and bottom lines as collaboration revenue slipped and losses widened. The clinical-stage oncology company reported Q1 2025 revenue of $5.39 million, falling 19.84% short of the $6.73 million consensus estimate and declining 16.7% from the year-ago period, driven primarily by lower research costs incurred under its collaboration, which reduced the amount of revenue recognized. EPS came in at -$0.36, missing the -$0.35 consensus by 4.08%, as the net loss widened to $39.88 million from $37.91 million in Q1 2024. In response to market conditions, Tango is scaling back preclinical spending and target discovery efforts, a strategic shift that extends its $216.70 million cash runway into Q1 2027. Looking ahead, the company expects a pivotal TNG462 Phase 1/2 clinical data update in the second half of 2025, with a combination trial alongside Revolution Medicines' RAS(ON) inhibitors set to begin enrolling in Q2 2025.
- Decreased collaboration revenue due to lower research costs under collaboration agreement
- Reduced R&D expenses from discontinued clinical programs TNG908 and TNG348
- Increased R&D spend on advancement of TNG961 and TNG456
- Higher G&A expenses due to increased personnel-related costs
“Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor. We anticipate presenting a fulsome efficacy, safety and tolerability data update on TNG462 monotherapy later this year, with a focus on pancreatic and lung cancer, and remain on track with our goal of initiating our first TNG462 monotherapy registrational study in pancreatic cancer next year. We also are moving forward rapidly with key clinical combinations and, based on strong preclinical data, we are focused on combining TNG462 with Revolution Medicine's RAS(ON) inhibitors daraxonrasib and zoldonrasib in pancreatic and lung cancer. Finally, given market conditions and our strong conviction in TNG462, we have taken steps to extend our cash runway and focus resources on our PRMT5 programs, reducing spend on our preclinical pipeline and deferring some clinical combination studies designed primarily to assess tolerability with standard-of-care regimens.”
Tango Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Tango expects its cash position of $216.7 million in cash, cash equivalents, and marketable securities to fund operations into Q1 2027, extended through reduced preclinical pipeline spending, lower target discovery efforts and associated headcount, and deferral of certain clinical combination studies. Key upcoming milestones include a TNG462 Phase 1/2 clinical data update in 2H 2025, enrollment in the TNG462 + RAS(ON) inhibitor combination trial and TNG456 Phase 1/2 trial beginning in Q2 2025, a TNG260 clinical update in 2H 2025, and initiation of a TNG462 monotherapy registrational study in pancreatic cancer targeted for 2026.
TNGX YoY Financials
TNGX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.